These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9916605)

  • 41. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure.
    Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH
    Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group.
    Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN
    Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension.
    Wellington K; Faulds DM
    Drugs; 2002; 62(13):1983-2005. PubMed ID: 12215069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differential time effect profiles of amlodipine, as compared to valsartan, revealed by ambulatory blood pressure monitoring, self blood pressure measurements and dose omission protocol.
    Radauceanu A; Boivin JM; Bernaud C; Fay R; Zannad F;
    Fundam Clin Pharmacol; 2004 Aug; 18(4):483-91. PubMed ID: 15312156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Valsartan: a novel angiotensin type 1 receptor antagonist.
    Thürmann PA
    Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design.
    Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R
    Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Amlodipine/valsartan single-pill combination: a review of its use in the management of hypertension.
    Frampton JE; Scott LJ
    Am J Cardiovasc Drugs; 2009; 9(5):309-30. PubMed ID: 19791840
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of selective angiotensin II receptor blockade on sympathetic nerve activity in primary hypertensive subjects.
    Struck J; Muck P; Trübger D; Handrock R; Weidinger G; Dendorfer A; Dodt C
    J Hypertens; 2002 Jun; 20(6):1143-9. PubMed ID: 12023684
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
    Krum H; Nolly H; Workman D; He W; Roniker B; Krause S; Fakouhi K
    Hypertension; 2002 Aug; 40(2):117-23. PubMed ID: 12154100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial.
    Oparil S; Yarows SA; Patel S; Fang H; Zhang J; Satlin A
    Lancet; 2007 Jul; 370(9583):221-229. PubMed ID: 17658393
    [TBL] [Abstract][Full Text] [Related]  

  • 53. AT1-receptor blockade improves augmentation index: a double-blind, randomized, controlled study.
    Klingbeil AU; John S; Schneider MP; Jacobi J; Weidinger G; Schmieder RE
    J Hypertens; 2002 Dec; 20(12):2423-8. PubMed ID: 12473867
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years.
    Flynn JT; Meyers KE; Neto JP; de Paula Meneses R; Zurowska A; Bagga A; Mattheyse L; Shi V; Gupte J; Solar-Yohay S; Han G;
    Hypertension; 2008 Aug; 52(2):222-8. PubMed ID: 18591457
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC; Ayala DE; Khder Y; Calvo C
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
    Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
    Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Efficacy and safety of the single pill combination of valsartan 80 mg plus amlodipine 5 mg in mild to moderate essential hypertensive patients without adequate blood pressure control by monotherapy].
    Ke YN; Huang J; Zhu JR;
    Zhonghua Xin Xue Guan Bing Za Zhi; 2009 Sep; 37(9):794-9. PubMed ID: 20128376
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical advantage of valsartan.
    McInnes GT
    Cardiology; 1999; 91 Suppl 1():14-8. PubMed ID: 10449890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension.
    Wells T; Blumer J; Meyers KE; Neto JP; Meneses R; Litwin M; Vande Walle J; Solar-Yohay S; Shi V; Han G;
    J Clin Hypertens (Greenwich); 2011 May; 13(5):357-65. PubMed ID: 21545397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.